Sickle cell disease (SCD) is an inherited disease characterized by sickle-shaped red blood cells that can slow or block blood flow. It affects about 100,000 people in the United States, and occurs more commonly in people of African descent. SCD is considered as a hypercoagulable state and venous thromboembolism (VTE) is a serious disease-specific complication. However, there have been limited real-world studies on VTE in SCD patients. This work aims to provide a comprehensive assessment of the risk factors and treatment of VTE in adults with SCD by using longitudinal real-world data. First, a retrospective cohort study on 30-day readmission was conducted to give a general understanding of the treatment of SCD. It was found that SCD patients were at high risk of readmission, and younger adults had higher risk than older adults. The risk factors vary significantly by age. These findings suggest that multifaceted, age-specific interventions are needed to improve the clinical outcomes of SCD patients. Second, the treatment patterns of pharmacological anticoagulation in adults with SCD was studied by using a retrospective, repeated cross-sectional design. The results may contribute to the optimal selection of regimens or dosing and informed decision making on anticoagulant utilization in routine care. Third, the incidence of VTE and its associated risk factors and clinical outcomes were examined. Several SCD-related complications and treatments were found to be significantly associated with VTE. Landmark survival analysis demonstrated that early management of VTE may improve the overall survival of SCD patients.
","abstract_html":"<p>Sickle cell disease (SCD) is an inherited disease characterized by sickle-shaped red blood cells that can slow or block blood flow. It affects about 100,000 people in the United States, and occurs more commonly in people of African descent. SCD is considered as a hypercoagulable state and venous thromboembolism (VTE) is a serious disease-specific complication. However, there have been limited real-world studies on VTE in SCD patients. This work aims to provide a comprehensive assessment of the risk factors and treatment of VTE in adults with SCD by using longitudinal real-world data. First, a retrospective cohort study on 30-day readmission was conducted to give a general understanding of the treatment of SCD. It was found that SCD patients were at high risk of readmission, and younger adults had higher risk than older adults. The risk factors vary significantly by age. These findings suggest that multifaceted, age-specific interventions are needed to improve the clinical outcomes of SCD patients. Second, the treatment patterns of pharmacological anticoagulation in adults with SCD was studied by using a retrospective, repeated cross-sectional design. The results may contribute to the optimal selection of regimens or dosing and informed decision making on anticoagulant utilization in routine care. Third, the incidence of VTE and its associated risk factors and clinical outcomes were examined. Several SCD-related complications and treatments were found to be significantly associated with VTE. Landmark survival analysis demonstrated that early management of VTE may improve the overall survival of SCD patients.</p>","abstract_has_math":false,"creators":["Chen, Ming"],"institution":null,"degree_name":"Doctor of Philosophy (PhD)","degree_level":"Dissertation","degree_discipline":"Health Outcomes and Policy Research","degree_department":null,"school":null,"contributors":["James Bailey, MD"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024-01-01T08:00:00Z","date_published":"2024-01-01T08:00:00Z","updated_at":"2026-07-24T05:00:53Z","subjects":["Longitudinal study","Real-world evidence","Risk factors","Survival analysis","Congenital, Hereditary, and Neonatal Diseases and Abnormalities","Diseases","Health and Medical Administration","Hemic and Lymphatic Diseases","Medicine and Health Sciences","Quality Improvement"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://dc.uthsc.edu/dissertations/689","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["James Bailey, MD"]},{"key":"dc:creator","label":"Author","values":["Chen, Ming"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2026-08-09T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Health Outcomes and Policy Research"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (PhD)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Longitudinal study","Real-world evidence","Risk factors","Survival analysis","Congenital, Hereditary, and Neonatal Diseases and Abnormalities","Diseases","Health and Medical Administration","Hemic and Lymphatic Diseases","Medicine and Health Sciences","Quality Improvement"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://dc.uthsc.edu/dissertations/689"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Sickle cell disease (SCD) is an inherited disease characterized by sickle-shaped red blood cells that can slow or block blood flow. It affects about 100,000 people in the United States, and occurs more commonly in people of African descent. SCD is considered as a hypercoagulable state and venous thromboembolism (VTE) is a serious disease-specific complication. However, there have been limited real-world studies on VTE in SCD patients. This work aims to provide a comprehensive assessment of the risk factors and treatment of VTE in adults with SCD by using longitudinal real-world data. First, a retrospective cohort study on 30-day readmission was conducted to give a general understanding of the treatment of SCD. It was found that SCD patients were at high risk of readmission, and younger adults had higher risk than older adults. The risk factors vary significantly by age. These findings suggest that multifaceted, age-specific interventions are needed to improve the clinical outcomes of SCD patients. Second, the treatment patterns of pharmacological anticoagulation in adults with SCD was studied by using a retrospective, repeated cross-sectional design. The results may contribute to the optimal selection of regimens or dosing and informed decision making on anticoagulant utilization in routine care. Third, the incidence of VTE and its associated risk factors and clinical outcomes were examined. Several SCD-related complications and treatments were found to be significantly associated with VTE. Landmark survival analysis demonstrated that early management of VTE may improve the overall survival of SCD patients.
"]},{"key":"dc:title","label":"Title","values":["Real-world Pharmacological Anticoagulation and Clinical Outcomes of Venous Thromboembolism in Adults with Sickle Cell Disease"]}]}],"canonical_facts":{"dc:contributor":["James Bailey, MD"],"dc:creator":["Chen, Ming"],"dc:date.available":["2026-08-09T07:00:00Z"],"dc:description.abstract":["Sickle cell disease (SCD) is an inherited disease characterized by sickle-shaped red blood cells that can slow or block blood flow. It affects about 100,000 people in the United States, and occurs more commonly in people of African descent. SCD is considered as a hypercoagulable state and venous thromboembolism (VTE) is a serious disease-specific complication. However, there have been limited real-world studies on VTE in SCD patients. This work aims to provide a comprehensive assessment of the risk factors and treatment of VTE in adults with SCD by using longitudinal real-world data. First, a retrospective cohort study on 30-day readmission was conducted to give a general understanding of the treatment of SCD. It was found that SCD patients were at high risk of readmission, and younger adults had higher risk than older adults. The risk factors vary significantly by age. These findings suggest that multifaceted, age-specific interventions are needed to improve the clinical outcomes of SCD patients. Second, the treatment patterns of pharmacological anticoagulation in adults with SCD was studied by using a retrospective, repeated cross-sectional design. The results may contribute to the optimal selection of regimens or dosing and informed decision making on anticoagulant utilization in routine care. Third, the incidence of VTE and its associated risk factors and clinical outcomes were examined. Several SCD-related complications and treatments were found to be significantly associated with VTE. Landmark survival analysis demonstrated that early management of VTE may improve the overall survival of SCD patients.
"],"dc:identifier":["https://dc.uthsc.edu/dissertations/689"],"dc:subject":["Longitudinal study","Real-world evidence","Risk factors","Survival analysis","Congenital, Hereditary, and Neonatal Diseases and Abnormalities","Diseases","Health and Medical Administration","Hemic and Lymphatic Diseases","Medicine and Health Sciences","Quality Improvement"],"dc:title":["Real-world Pharmacological Anticoagulation and Clinical Outcomes of Venous Thromboembolism in Adults with Sickle Cell Disease"],"thesis:degree_discipline":["Health Outcomes and Policy Research"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Doctor of Philosophy (PhD)"]},"updated_at":"2026-07-24T05:00:53Z"}